Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s website.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VNDA:
- Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
- Vanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210M
- Vanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Vanda Pharmaceuticals initiated with a Buy at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
